Viamet commences VT-1161 Phase 1 clinical study to treat fungal infections

Links shared publicly online about this topic.

0
total visits

Viamet commences VT-1161 Phase 1 clinical study to treat fungal infections

Viamet Pharmaceuticals, Inc., announced today that dosing has begun in a Phase 1 clinical study of VT-1161, an oral, potent and selective antifungal agent. VT-1161 is a novel small molecule discovered by Viamet Pharmaceuticals using its proprietary Metallophile Technology.

View full resource at news-medical.net

Tags: Infection, Fungal Infection, Meningitis, Pharma, Phase 1 Clinical Trial, News